DOCSLIB.ORG

Prescription Drug List Products for Human

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prescription Drug List Products for Human Prescription Drug List (Does not include medicinal ingredients listed in the Controlled Drugs and Substances Act Schedules) Products for Human Use Drugs containing any of the following: Including Effective date Qualifier (but not limited to) (yyyy-mm-dd) 2,4-Dinitrophenol or its salts or derivatives 2013-12-19 4-Amino-pteroyl aspartic acid or its salts 2013-12-19 4-Aminosalicylic Acid or its salts 2013-12-19 4-Hydroxycoumarin or its derivatives Acenocoumarol when sold or recommended as anticoagulants 2013-12-19 5-Aminosalicylic acid Mesalazine 2013-12-19 Abacavir or its salts 2013-12-19 Abatacept 2013-12-19 Abciximab 2013-12-19 Abiraterone or its derivatives Abiraterone acetate 2013-12-20 Acamprosate or its salts 2013-12-19 Acarbose or its derivatives 2013-12-19 Acebutolol or its salts 2013-12-19 Acepromazine or its salts 2013-12-19 Acetaminophen when recommended for administration by intravenous 2013-12-20 injection Acetanilide 2013-12-19 Acetazolamide 2013-12-19 Acetohexamide 2013-12-19 Acetylcarbromal 2013-12-19 Acetylcholine Chloride 2013-12-19 Acitretin or its salts or derivatives 2013-12-19 Aclidinium or its salts 2013-12-20 Aconiazide or its salts 2013-12-19 Acyclovir or its salts 2013-12-19 Adalimumab 2013-12-19 Adapalene or its salts or derivatives 2013-12-19 Adefovir or its salts or derivatives Adefovir dipivoxil 2013-12-19 Adenosine or its salts when sold or recommended for administration by 2013-12-19 intravenous injection Page 1 2017/08/04 Adrenocortical hormones or their salts or Betamethasone valerate, except: 2016-08-26 derivatives betamethasone sodium, a.hydrocortisone or hydrocortisone acetate, when sold as betamethasone phosphate, betamethasone dipropionate, a single medicinal ingredient in a concentration that budesonide, provides 1.0% or less hydrocortisone in preparations for ciclesonide, topical use on the skin; or, clobetasone, b.hydrocortisone or hydrocortisone acetate, when sold in cortisone, combination with any other nonprescription medicinal dexamethasone sodium, dexamethasone phosphate, ingredient that provides 1.0% or less hydrocortisone in dexamethasone acetate, preparations for topical use on the skin; or, difluprednate, c.clobetasone butyrate when sold in a concentration of fludrocortisone acetate, 0.05% in cream preparations for topical use on the skin; flunisolide, fluticasone propionate, or, fluticasone furoate, d. triamcinolone acetonide in a nasal spray that delivers hydrocortisone acetate, 55 microgram/spray for those 12 years of age and older; hydrocortisone aceponate, or, hydrocortisone sodium, e. Mometasone furoate for the treatment of allergic methylprednisolone acetate, methylprednisolone, rhinitis in a nasal spray that delivers 50 microgram/spray methylprednisolone succinate, for those 12 years of age and older. methylprednisolone sodium, f. Fluticasone propionate for the treatment of allergic mometasone furoate, rhinitis in a nasal spray that delivers 50 microgram/spray prednisolone acetate, prednisolone sodium, for those 18 years of age and older. prednisolone phosphate, prednisone, triamcinolone acetonide, triamcinolone hexacetonide Afatinib or its salts 2013-12-20 Aflibercept 2013-12-20 Afoxolaner 2014-08-21 Agalsidase Alfa, 2013-12-19 beta Albiglutide 2015-08-12 Aldesleukin 2013-12-19 Alectinib or its salts 2016-11-10 Alefacept 2013-12-19 Alemtuzumab 2013-12-19 Alendronic acid or its salts 2013-12-19 Alfacalcidol 2013-12-19 Alfuzosin or its salts 2013-12-19 Page 2 2017/08/04 Alglucosidase alfa 2013-12-19 Alirocumab 2016-08-09 Aliskiren or its salts 2013-12-19 Alitretinoin or its salts or derivatives 2013-12-20 Alkyl nitrites 2013-12-19 Allopurinol 2013-12-19 Allylisopropylacetylurea 2013-12-19 Almotriptan or its salts 2013-12-19 Alogliptin or its salts or derivatives 2013-12-20 Alpha-chloralose 2013-12-19 Alphadolone or its salts 2013-12-19 Alpha-hydroxy acids Citric acid, when sold in topical formulations containing alpha 2014-12-25 glycolic acid, hydroxy acids alone or in combination at concentrations lactic acid, greater than 30% and/or with a pH lower than 3.0, except malic acid, when sold to be applied to warts, corns or calluses. mandelic acid, ammonium glycolate, glycolic acid + ammonium glycolate, alpha-hydroxyethanoic acid + ammonium alpha-hydroxyethanoate, alpha-hydroxyoctanoic acid, alpha-hydroxycaprylic acid, hydroxycaprylic acid, mixed fruit acid, triple fruit acid, tri-alpha hydroxy fruit acids, alpha hydroxy and botanical complex, l-alpha hydroxy acid, glycomer in cross-linked fatty acids alpha nutrium Alphaxalone Alfaxalone, 2013-12-19 alphaxolone Alteplase or its salts or derivatives Tenecteplase 2013-12-19 Altrenogest 2013-12-19 Altretamine 2013-12-19 Amantadine or its salts 2013-12-19 Ambenonium Chloride 2013-12-19 Ambrisentan 2013-12-19 Page 3 2017/08/04 Amifostine or its salts 2013-12-19 Amikacin or its salts or derivatives Amikacin sulfate 2013-12-19 Amiloride or its salts 2013-12-19 Aminocaproic acid 2013-12-19 Aminoglutethimide 2013-12-19 Aminolevulinic acid or its salts or 2013-12-19 derivatives Aminophylline 2013-12-19 Aminopterin or its salts or derivatives 2013-12-19 Aminopyrine or its derivatives 2013-12-19 Amiodarone or its salts or derivatives Dronedarone 2013-12-19 Amitraz 2013-12-19 Amitriptyline or its salts 2013-12-19 Amlexanox or its salts or derivatives 2013-12-19 Amlodipine or its salts 2013-12-19 Ammonium bromide 2013-12-19 Amoxapine 2013-12-19 Amphotericin B or its salts or derivatives 2013-12-19 Amprenavir or its salts or derivatives Fosamprenavir 2013-12-19 Amprolium or its salts 2013-12-19 Amrinone or its salts 2013-12-19 Amsacrine or its salts 2013-12-19 Anagrelide or its salts 2013-12-19 Anakinra or its salts or derivatives 2013-12-19 Anastrozole 2013-12-19 Ancestim 2013-12-19 Anidulafungin 2013-12-19 Antipyrine except preparations for topical use 2013-12-19 Anti-thymocyte globulin 2013-12-19 Apixaban or its derivatives 2013-12-20 Apomorphine or its salts 2017-02-10 Apraclonidine or its salts 2013-12-19 Apramycin or its salts 2013-12-19 Apremilast 2014-12-04 Aprepitant or its derivatives Fosaprepitant 2013-12-19 Aprotinin 2013-12-19 Argatroban or its salts or derivatives 2013-12-19 Page 4 2017/08/04 Aripiprazole or its salts 2013-12-20 Arsenic trioxide 2013-12-19 Asenapine or its salts or derivatives Asenapine maleate 2013-12-20 Asfotase alfa 2015-10-16 Asparaginase when sold for administration by injection 2013-12-19 Astemizole or its salts 2013-12-19 Asunaprevir 2016-08-26 Atazanavir or its salts 2013-12-19 Atenolol or its salts 2013-12-19 Atezolizumab 2017-05-16 Atipamezole or its salts 2013-12-19 Atomoxetine or its salts 2013-12-19 Atorvastatin or its salts 2013-12-19 Atovaquone 2013-12-19 Atracurium besilate 2013-12-19 Atropine or its salts Atropine sulphate in ophthalmic or parenteral preparations 2013-12-19 Avermectin or its derivatives Ivermectin, 2013-12-19 selamectin, doramectin Avilamycin or its salts or derivatives 2014-03-12 Axitinib or its salts or derivatives 2013-12-20 Azacitidine or its salts or derivatives 2013-12-20 Azacyclonol or its salts 2013-12-19 Azaribine 2013-12-19 Azathioprine or its salts 2013-12-19 Azatidine or its salts or derivatives Azatadine 2013-12-19 Azelaic acid 2013-12-19 Azelastine or its salts 2014-12-05 Azilsartan medoxomil or its salts or 2013-12-20 derivatives Azithromycin or its salts or derivatives 2013-12-19 Aztreonam or its salts 2013-12-19 Baclofen or its salts 2013-12-19 Bambuterol or its salts 2013-12-19 Basiliximab 2013-12-19 Bazedoxifene or its salts 2014-12-04 Becaplermin 2013-12-19 Page 5 2017/08/04 Belimumab 2013-12-20 Bemegride 2013-12-19 Benactyzine or its salts 2013-12-19 Benazepril or its salts or derivatives Benazepril hydrochloride 2013-12-19 Bendamustine or its salts or derivatives Bendamustine hydrochloride 2013-12-20 Bendazac or its salts 2013-12-19 Benoxaprofen or its salts 2013-12-19 Benserazide or its salts 2013-12-19 Benzoyl peroxide in concentrations greater than 5% or when sold in 2013-12-19 combination with another medicinal ingredient Benztropine or its salts Benzatropine 2013-12-19 Benzydamine or its salts 2013-12-19 Bepotastine or its salts or derivatives 2016-11-10 Beractant 2013-12-19 Besifloxacin or its salts 2013-12-20 Betahistine or its salts 2013-12-19 Betaine or its salts when sold or recommended for the treatment of 2013-12-19 homocystinuria Betaxolol or its salts 2013-12-19 Bethanechol chloride 2013-12-19 Bethanidine or its salts 2013-12-19 Bevacizumab 2013-12-19 Bezafibrate or its salts or derivatives 2013-12-19 Bicalutamide 2013-12-19 Bilastine or its salts or derivatives 2016-08-26 Biperiden or its salts 2013-12-19 Bishydroxycoumarin or its salts or 2013-12-19 derivatives Bisoprolol or its salts 2013-12-19 Bitolterol or its salts 2013-12-19 Bivalirudin 2013-12-19 Bleomycin 2013-12-19 Blinatumomab 2016-08-09 Boceprevir or its derivatives 2013-12-20 Bortezomib 2013-12-19 Bosentan or its salts or derivatives 2013-12-19 Bosutinib or its salts Bosutinib methanoate 2014-08-21 Page 6 2017/08/04 Botulinum toxin Onabotulinumtoxin A, 2013-12-19 incobotulinumtoxin A, abobotulinumtoxin A, rimabotulinumtoxin B Brentuximab Vedotin 2013-12-20 Bretylium tosylate 2013-12-19 Brexpiprazole or its salts 2017-04-21 Brimonidine or its salts 2013-12-19 Brivaracetam or its derivatives 2016-08-09 Bromal 2013-12-19 Bromal hydrate 2013-12-19 Brometone 2013-12-19 Bromfenac or its salts 2015-05-28 Bromisoval 2013-12-19 Bromocriptine or its salts 2013-12-19 Bromoform 2013-12-19 Bumetanide or its salts or derivatives 2013-12-19 Bupropion or its salts 2013-12-19 Buserelin
Load more

Recommended publications
  • Stable Isotope-Labeled Productsfor Metabolic Research
    RESEARCH PRODUCTS Cambridge Isotope Laboratories, Inc. isotope.com Stable Isotope-Labeled Products For Metabolic Research Cambridge Isotope Laboratories, Inc. North America: 1.800.322.1174 [email protected] | International: +1.978.749.8000 [email protected] | fax: 1.978.749.2768 | isotope.com Cambridge Isotope Laboratories, Inc. | Stable Isotope-Labeled Products for Metabolic Research Stable Isotopes in Metabolomics and Metabolism Gary J. Patti Department of Chemistry, Washington University, St. Louis, Missouri 63130 United States Recent advances in mass spectrometry (MS) and nuclear comparing two sample groups, for example, an elevated magnetic resonance (NMR) technologies have greatly metabolite level may indicate increased or decreased enhanced metabolite analysis. Hundreds to thousands pathway flux. This is because metabolites can accumulate of metabolites can now be measured simultaneously with not only due to increased production, but also due to unprecedented accuracy from exceedingly small amounts decreased consumption. Yet, the difference between of biological material. These technical developments have increased production and decreased consumption may yield given rise to the field of metabolomics, which generally entirely different experimental interpretations. In a biomedical aims to assess metabolic regulation as a function of health context, for instance, increased production of a metabolite and disease. During the last decade, it has become relatively may suggest pharmacological inhibition of the pathway as a routine to perform metabolomic analysis on most biological therapeutic strategy. Thus, to understand pathway regulation samples. Interpretation of the acquired data, however, and metabolic mechanisms of disease, the application of remains a considerable challenge. Stable isotopes are isotopic tracers is required. providing experimental strategies that overcome some of these barriers.
    [Show full text]
  • Spirometry Protocol and Software Training Handout
    SPIROMETRY PROTOCOL AND SOFTWARE TRAINING HANDOUT Spirometry Protocol Key Points in Performing Spirometry ▪ Always demonstrate the maneuver ▪ Prompt the participant to BLAST out the air ▪ Continue by having the participant PUSH out the air ▪ Continue until the balloon bursts or at least six seconds Getting ready to do Spirometry Subjects will be instructed to not use any bronchodilator medicines for at least 4 hours prior to the appointment (in the case of salmeterol [Serevent] or Fomoterol (foradil)or Tritoprium (Spiriva) avoid for 12 hours prior to the test). Bronchodilator medicines include: Short acting bronchodilators Albuterol (ventolin, proventil, airet, volmax tablet) Levalbuterol (xopenex) Metaproterenol (alupent) Pirbuterol (maxair) Terbutaline (brethaire, brethine, bricanyl) Isoetharine (bronkosol) Ipratropium (atrovent) Ipratropium and albuterol combination (Combivent) Isoproteranol (isuprel) Primatine 1 CHW Educational Protocols – Spirometry Protocol and Software Training Handout Bitolterol (tornalate) Long acting bronchodilator Salmeterol (serevent) Fomoterol (foradil) Tritoprium (Spiriva) Bronchodilators should be avoided because they can affect the spirometry results. If the patient is having symptoms from asthma and needs to use the medicine, ask that the medicine be used 4 hours before the visit, so that the next dose is due during the visit. Patients can then do the spirometry and then the patient can take the medicine after the test is completed. When scheduling the follow-up spirometry visit, if at all possible, try to make the visit at the same time as the initial baseline visit. 1. Preparing the Computer 1. Check to see if the time and date on the lower right hand corner is current. If the date and time is NOT, the spirometer will NOT sync with the computer or the Easy One software.
    [Show full text]
  • Catalog Stable Isotope-Labeled Products for Metabolic Research
    Cambridge Isotope Laboratories, Inc. isotope.com Stable Isotope-Labeled Products For Metabolic Research Euriso-Top, Parc des Algorithmes, route de l'orme, 91190 Saint Aubin | France tel: +33 1 69 41 97 98 fax: +33 1 69 41 93 52 +49 (0) 681 99 63 338 (Germany) www.eurisotop.com Cambridge Isotope Laboratories, Inc. | Stable Isotope-Labeled Products for Metabolic Research Stable Isotopes in Metabolomics and Metabolism Gary J. Patti Department of Chemistry, Washington University, St. Louis, Missouri 63130 United States Recent advances in mass spectrometry (MS) and nuclear comparing two sample groups, for example, an elevated magnetic resonance (NMR) technologies have greatly metabolite level may indicate increased or decreased enhanced metabolite analysis. Hundreds to thousands pathway flux. This is because metabolites can accumulate of metabolites can now be measured simultaneously with not only due to increased production, but also due to unprecedented accuracy from exceedingly small amounts decreased consumption. Yet, the difference between of biological material. These technical developments have increased production and decreased consumption may yield given rise to the field of metabolomics, which generally entirely different experimental interpretations. In a biomedical aims to assess metabolic regulation as a function of health context, for instance, increased production of a metabolite and disease. During the last decade, it has become relatively may suggest pharmacological inhibition of the pathway as a routine to perform metabolomic analysis on most biological therapeutic strategy. Thus, to understand pathway regulation samples. Interpretation of the acquired data, however, and metabolic mechanisms of disease, the application of remains a considerable challenge. Stable isotopes are isotopic tracers is required.
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Evaluation of Fluralaner and Afoxolaner Treatments to Control Flea
    Dryden et al. Parasites & Vectors (2016) 9:365 DOI 10.1186/s13071-016-1654-7 RESEARCH Open Access Evaluation of fluralaner and afoxolaner treatments to control flea populations, reduce pruritus and minimize dermatologic lesions in naturally infested dogs in private residences in west central Florida USA Michael W. Dryden1*, Michael S. Canfield2, Kimberly Kalosy1, Amber Smith1, Lisa Crevoiserat1, Jennifer C. McGrady1, Kaitlin M. Foley1, Kathryn Green2, Chantelle Tebaldi2, Vicki Smith1, Tashina Bennett1, Kathleen Heaney3, Lisa Math3, Christine Royal3 and Fangshi Sun3 Abstract Background: A study was conducted to evaluate and compare the effectiveness of two different oral flea and tick products to control flea infestations, reduce pruritus and minimize dermatologic lesions over a 12 week period on naturally infested dogs in west central FL USA. Methods: Thirty-four dogs with natural flea infestations living in 17 homes were treated once with a fluralaner chew on study day 0. Another 27 dogs living in 17 different homes were treated orally with an afoxolaner chewable on day 0, once between days 28–30 and once again between days 54–60. All products were administered according to label directions by study investigators. Flea populations on pets were assessed using visual area counts and premise flea infestations were assessed using intermittent-light flea traps on days 0, 7, 14, 21, and once between days 28–30, 40–45, 54–60 and 82–86. Dermatologic assessments were conducted on day 0 and once monthly. Pruritus assessments were conducted by owners throughout the study. No concurrent treatments for existing skin disease (antibiotics, anti-inflammatories, anti-fungals) were allowed.
    [Show full text]
  • WO 2010/015655 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 11 February 2010 (11.02.2010) WO 2010/015655 Al (51) International Patent Classification: sham Research Centre, Wimblehurst Road, Horsham C07C 233/79 (2006.01) C07D 277/42 (2006.01) West Sussex RH 12 5AB (GB). SVIRIDENKO, Lilya C07C 255/58 (2006.01) A61K 31/166 (2006.01) [GB/GB]; Novartis Horsham Research Centre, Wimble C07C 311/39 (2006.01) A61K 31/427 (2006.01) hurst Road, Horsham West Sussex RH 12 5AB (GB). C07D 213/74 (2006.01) A61K 31/44 (2006.01) (74) Agent: VOEGELI-LANGE, Regina; Novartis Pharma C07D 213/75 (2006.01) A61P 1/00 (2006.01) Ag, Patent Department, CH-4002 Basel (CH). C07D 213/84' (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/EP2009/060150 AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (22) International Filing Date: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, 5 August 2009 (05.08.2009) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (25) Filing Language: English KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (26) Publication Language: English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (30) Priority Data: SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, 08162006.4 7 August 2008 (07.08.2008) EP TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • B Commission Regulation (Eu)
    02010R0037 — EN — 29.09.2018 — 035.001 — 1 This text is meant purely as a documentation tool and has no legal effect. The Union's institutions do not assume any liability for its contents. The authentic versions of the relevant acts, including their preambles, are those published in the Official Journal of the European Union and available in EUR-Lex. Those official texts are directly accessible through the links embedded in this document ►B COMMISSION REGULATION (EU) No 37/2010 of 22 December 2009 on pharmacologically active substances and their classification regarding maximum residue limits in foodstuffs of animal origin (Text with EEA relevance) (OJ L 15, 20.1.2010, p. 1) Amended by: Official Journal No page date ►M1 Commission Regulation (EU) No 758/2010 of 24 August 2010 L 223 37 25.8.2010 ►M2 Commission Regulation (EU) No 759/2010 of 24 August 2010 L 223 39 25.8.2010 ►M3 Commission Regulation (EU) No 761/2010 of 25 August 2010 L 224 1 26.8.2010 ►M4 Commission Regulation (EU) No 890/2010 of 8 October 2010 L 266 1 9.10.2010 ►M5 Commission Regulation (EU) No 914/2010 of 12 October 2010 L 269 5 13.10.2010 ►M6 Commission Regulation (EU) No 362/2011 of 13 April 2011 L 100 26 14.4.2011 ►M7 Commission Regulation (EU) No 363/2011 of 13 April 2011 L 100 28 14.4.2011 ►M8 Commission Implementing Regulation (EU) No 84/2012 of 1 L 30 1 2.2.2012 February 2012 ►M9 Commission Implementing Regulation (EU) No 85/2012 of 1 L 30 4 2.2.2012 February 2012 ►M10 Commission Implementing Regulation (EU) No 86/2012 of 1 L 30 6 2.2.2012 February 2012 ►M11 Commission
    [Show full text]
  • United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar
    USOO896.9514B2 (12) United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar. 3, 2015 (54) AGONISTS OF GUANYLATECYCLASE 5,879.656 A 3, 1999 Waldman USEFUL FOR THE TREATMENT OF 36; A 6. 3: Watts tal HYPERCHOLESTEROLEMIA, 6,060,037- W - A 5, 2000 Waldmlegand et al. ATHEROSCLEROSIS, CORONARY HEART 6,235,782 B1 5/2001 NEW et al. DISEASE, GALLSTONE, OBESITY AND 7,041,786 B2 * 5/2006 Shailubhai et al. ........... 530.317 OTHER CARDOVASCULAR DISEASES 2002fOO78683 A1 6/2002 Katayama et al. 2002/O12817.6 A1 9/2002 Forssmann et al. (75) Inventor: Kunwar Shailubhai, Audubon, PA (US) 2003,2002/0143015 OO73628 A1 10/20024, 2003 ShaubhaiFryburg et al. 2005, OO16244 A1 1/2005 H 11 (73) Assignee: Synergy Pharmaceuticals, Inc., New 2005, OO32684 A1 2/2005 Syer York, NY (US) 2005/0267.197 A1 12/2005 Berlin 2006, OO86653 A1 4, 2006 St. Germain (*) Notice: Subject to any disclaimer, the term of this 299;s: A. 299; NS et al. patent is extended or adjusted under 35 2008/0137318 A1 6/2008 Rangarajetal.O U.S.C. 154(b) by 742 days. 2008. O151257 A1 6/2008 Yasuda et al. 2012/O196797 A1 8, 2012 Currie et al. (21) Appl. No.: 12/630,654 FOREIGN PATENT DOCUMENTS (22) Filed: Dec. 3, 2009 DE 19744O27 4f1999 (65) Prior Publication Data WO WO-8805306 T 1988 WO WO99,26567 A1 6, 1999 US 2010/O152118A1 Jun. 17, 2010 WO WO-0 125266 A1 4, 2001 WO WO-02062369 A2 8, 2002 Related U.S.
    [Show full text]
  • Medicines Regulations 1984 (SR 1984/143)
    Reprint as at 1 July 2014 Medicines Regulations 1984 (SR 1984/143) David Beattie, Governor-General Order in Council At the Government House at Wellington this 5th day of June 1984 Present: His Excellency the Governor-General in Council Pursuant to section 105 of the Medicines Act 1981, and, in the case of Part 3 of the regulations, to section 62 of that Act, His Excellency the Governor-General, acting on the advice of the Minister of Health tendered after consultation with the organisations and bodies that ap- peared to the Minister to be representatives of persons likely to be substantially affected, and by and with the advice and consent of the Executive Council, hereby makes the following regulations. Contents Page 1 Title and commencement 5 Note Changes authorised by subpart 2 of Part 2 of the Legislation Act 2012 have been made in this official reprint. Note 4 at the end of this reprint provides a list of the amendments incorporated. These regulations are administered by the Ministry of Health. 1 Reprinted as at Medicines Regulations 1984 1 July 2014 2 Interpretation 5 Part 1 Classification of medicines 3 Classification of medicines 11 Part 2 Standards 4 Standards for medicines, related products, medical 11 devices, cosmetics, and surgical dressings 5 Pharmacist may dilute medicine in particular case 12 6 Colouring substances [Revoked] 12 Part 3 Advertisements 7 Advertisements not to claim official approval 13 8 Advertisements for medicines 13 9 Advertisements for related products 15 10 Advertisements for medical devices 15 11 Advertisements
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Us Anti-Doping Agency
    2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used
    [Show full text]
  • Part I Biopharmaceuticals
    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
    [Show full text]